Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients-Reference-Cited by-同舟云学术

Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients

Published:2015-12 Issue:6 Volume:4 Page:381-386
ISSN:2045-0907
Container-title:CNS Oncology
language:en
Short-container-title:CNS Oncology

Author:

Le Rhun Emilie¹²³,Chamberlain Marc C⁴,Zairi Fahed³⁵,Delmaire Christine⁶,Idbaih Ahmed⁷⁸,Renaud Florence⁹¹⁰¹¹,Maurage Claude Alain⁹¹⁰¹¹,Grégoire Valérie⁹¹⁰¹¹

Affiliation:

1. Neuro-Oncology, Neurosurgery Department, University Hospital – CHRU Lille, France

2. Neurology, Medical Oncology Department, Oscar Lambret Center, Lille, France

3. Inserm, U1192, Lille, France

4. Neurology & Neurological Surgery, University of Washington, Fred Hutchinson Research Cancer Center, Seattle, WA 98109, USA

5. Neurosurgery Department, University Hospital – CHRU Lille, France

6. Neuroradiology Department, University Hospital – CHRU Lille, France

7. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de neurologie 2-Mazarin; Sorbonne Universités, UPMC Univ Paris 06, UM 75

8. Inserm, U 1127, CNRS, UMR 7225, ICM, F-75013 Paris, France

9. Neuropathology Department, University Hospital – CHRU Lille, France

10. Lille University, Lille, France

11. UMR-S, 1172 F-59000 Lille, France

Abstract

Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cns.15.30

Reference26 articles.

1. Standards of care for treatment of recurrent glioblastoma—are we there yet?

2. Rapid aneurysm growth and rupture in systemic lupus erythematosus

3. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme

4. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma

5. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression;Molecular Pharmaceutics;2023-11-08

2. ALK fusions in the pan-cancer setting: another tumor-agnostic target?;npj Precision Oncology;2023-09-29

3. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery;Pharmaceutics;2022-12-24

4. Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?;Frontiers in Oncology;2022-07-06

5. Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug;Future Journal of Pharmaceutical Sciences;2021-09-08